RATIONALE: Low-dose vitamin D supplementation is already recommended in older adults for prevention of fractures and falls, but clinical trials investigating whether higher doses could provide additional protection against acute respiratory infection (ARI) are lacking. OBJECTIVE: To conduct a clinical trial of high-dose versus low-dose vitamin D3 supplementation for ARI prevention in residents of sheltered-accommodation housing blocks ('schemes') and their carers in London, UK. MEASUREMENTS AND METHODS: Fifty-four schemes (137 individual participants) were allocated to the active intervention (vitamin D3 2.4 mg once every 2 months +10 μg daily for residents, 3 mg once every 2 months for carers), and 54 schemes with 103 participants were allocated to control (placebo once every 2 months +vitamin D3 10 μg daily for residents, placebo once every 2 months for carers) for 1 year. Primary outcome was time to first ARI; secondary outcomes included time to first upper/lower respiratory infection (URI/LRI, analysed separately), and symptom duration. MAIN RESULTS: Inadequate vitamin D status was common at baseline: 220/240 (92%) participants had serum 25(OH)D concentration <75 nmol/L. The active intervention did not influence time to first ARI (adjusted HR (aHR) 1.18, 95% CI 0.80 to 1.74, p=0.42). When URI and LRI were analysed separately, allocation to the active intervention was associated with increased risk of URI (aHR 1.48, 95% CI 1.02 to 2.16, p=0.039) and increased duration of URI symptoms (median 7.0 vs 5.0 days for active vs control, adjusted ratio of geometric means 1.34, 95% CI 1.09 to 1.65, p=0.005), but not with altered risk or duration of LRI. CONCLUSIONS: Addition of intermittent bolus-dose vitamin D3 supplementation to a daily low-dose regimen did not influence risk of ARI in older adults and their carers, but was associated with increased risk and duration of URI. TRIAL REGISTRATION NUMBER: clinicaltrials.gov NCT01069874. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
RATIONALE: Low-dose vitamin D supplementation is already recommended in older adults for prevention of fractures and falls, but clinical trials investigating whether higher doses could provide additional protection against acute respiratory infection (ARI) are lacking. OBJECTIVE: To conduct a clinical trial of high-dose versus low-dose vitamin D3 supplementation for ARI prevention in residents of sheltered-accommodation housing blocks ('schemes') and their carers in London, UK. MEASUREMENTS AND METHODS: Fifty-four schemes (137 individual participants) were allocated to the active intervention (vitamin D3 2.4 mg once every 2 months +10 μg daily for residents, 3 mg once every 2 months for carers), and 54 schemes with 103 participants were allocated to control (placebo once every 2 months +vitamin D3 10 μg daily for residents, placebo once every 2 months for carers) for 1 year. Primary outcome was time to first ARI; secondary outcomes included time to first upper/lower respiratory infection (URI/LRI, analysed separately), and symptom duration. MAIN RESULTS: Inadequate vitamin D status was common at baseline: 220/240 (92%) participants had serum 25(OH)D concentration <75 nmol/L. The active intervention did not influence time to first ARI (adjusted HR (aHR) 1.18, 95% CI 0.80 to 1.74, p=0.42). When URI and LRI were analysed separately, allocation to the active intervention was associated with increased risk of URI (aHR 1.48, 95% CI 1.02 to 2.16, p=0.039) and increased duration of URI symptoms (median 7.0 vs 5.0 days for active vs control, adjusted ratio of geometric means 1.34, 95% CI 1.09 to 1.65, p=0.005), but not with altered risk or duration of LRI. CONCLUSIONS: Addition of intermittent bolus-dose vitamin D3 supplementation to a daily low-dose regimen did not influence risk of ARI in older adults and their carers, but was associated with increased risk and duration of URI. TRIAL REGISTRATION NUMBER: clinicaltrials.gov NCT01069874. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Adit A Ginde; Patrick Blatchford; Keith Breese; Lida Zarrabi; Sunny A Linnebur; Jeffrey I Wallace; Robert S Schwartz Journal: J Am Geriatr Soc Date: 2016-11-16 Impact factor: 5.562
Authors: Christine Rake; Clare Gilham; Laurette Bukasa; Richard Ostler; Michelle Newton; James Peto Wild; Benoit Aigret; Michael Hill; Oliver Gillie; Irwin Nazareth; Peter Sasieni; Adrian Martineau; Julian Peto Journal: Health Technol Assess Date: 2020-02 Impact factor: 4.014
Authors: David A Jolliffe; Christos Stefanidis; Zhican Wang; Nazanin Z Kermani; Vassil Dimitrov; John H White; John E McDonough; Wim Janssens; Paul Pfeffer; Christopher J Griffiths; Andrew Bush; Yike Guo; Stephanie Christenson; Ian M Adcock; Kian Fan Chung; Kenneth E Thummel; Adrian R Martineau Journal: Am J Respir Crit Care Med Date: 2020-08-01 Impact factor: 21.405
Authors: Margaret T Lee; Meyer Kattan; Ilene Fennoy; Stephen M Arpadi; Rachel L Miller; Serge Cremers; Donald J McMahon; Jeri W Nieves; Gary M Brittenham Journal: Blood Adv Date: 2018-05-08
Authors: A M S Ahmed; T Ahmed; R J Soares Magalhaes; K Z Long; M A Alam; M I Hossain; M M Islam; M Mahfuz; D Mondal; R Haque; A Al Mamun Journal: Epidemiol Infect Date: 2016-08-11 Impact factor: 4.434
Authors: Balázs Odler; István Ivancsó; Vivien Somogyi; Kálmán Benke; Lilla Tamási; Gabriella Gálffy; Balázs Szalay; Veronika Müller Journal: Int J Chron Obstruct Pulmon Dis Date: 2015-09-24